Výsledky vyhledávání - "SAMYSHKIN, Y"

Akademický článek

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States

Autor: Shah A, Tosh JC, Ambavane A, Nikolaou A, Hogea C, Samyshkin Y, Gorsh B, Maiese EM, Wang F

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 13, Pp 789-800 (2021)

Anshul Shah,1 Jonathan C Tosh,2 Apoorva Ambavane,2 Andreas Nikolaou,2 Cosmina Hogea,3 Yevgeniy Samyshkin,4 Boris Gorsh,3 Eric M Maiese,5 Feng Wang3 1Modelling and Simulation, Evidera, Waltham, MA, USA; 2Modelling and Simulation, Evidera, London, UK;

Externí odkaz: https://doaj.org/article/e42a19c1e9db44059838690b6f2258f1

Zobrazit plný text záznamu

Akademický článek

EP.11A.12 Real-World Treatment Patterns and Clinical Outcomes Following Chemotherapy and Anti-PD-(L)1 In Non-Small Cell Lung Cancer.

Autor: Velcheti, V., Moore, J., Wang, H., Zhu, X., Samyshkin, Y., Ward, T., Christensen, A., Solem, C.

Publikováno v: Journal of Thoracic Oncology; 2024 Supplement, Vol. 19 Issue 10, pS600-S601, 2p

Zobrazit plný text záznamu

Akademický článek

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland

Autor: Samyshkin Y, Schlunegger M, Haefliger S, Ledderhose S, Radford M

Publikováno v: International Journal of COPD, Vol 2013, Iss default, Pp 79-87 (2013)

Yevgeniy Samyshkin,1 Michael Schlunegger,2 Susan Haefliger,3 Sabine Ledderhose,3 Matthew Radford11IMS Health, Health Economics and Outcomes Research, London, United Kingdom; 2Marketing Specialty Care, 3Medical Department, Takeda Pharma AG, Pfäffikon

Externí odkaz: https://doaj.org/article/d35648a0cf174a6c9b43a733172d2966

Zobrazit plný text záznamu

Akademický článek

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis

Autor: Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K

Publikováno v: International Journal of COPD, Vol 2012, Iss default, Pp 183-199 (2012)

Nadine Hertel1, Robert W Kotchie1, Yevgeniy Samyshkin1, Matthew Radford1, Samantha Humphreys2, Kevin Jameson21IMS Consulting Group, London, UK; 2MSD Ltd, Hoddesdon, UKPurpose: Frequent exacerbations which are both costly and potentially life-threaten

Externí odkaz: https://doaj.org/article/0c5616147e584c6bbac0285b33fb8c1f

Zobrazit plný text záznamu